What is new in detrusor-sphincter dyssynergia treatment in spinal cord injury patients?

NeuroRehabilitation

Volumn 10, Issue 3, 1998, Pages 267-279

  Schurch, Brigitte ^a  

^a BALGRIST UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Botulinum A toxin; Detrusor sphincter dyssynergia; Electrical stimulation; Neurogenic bladder; Self catheterization

Indexed keywords

BOTULINUM TOXIN A; CHOLINERGIC RECEPTOR BLOCKING AGENT;

BLADDER CATHETERIZATION; BLADDER FUNCTION; BLADDER NECK STENOSIS; BLADDER SPHINCTER; BLADDER WALL; CONTINENCE; DETRUSOR DYSSYNERGIA; ELECTROSTIMULATION; HUMAN; PELVIC NERVE; REVIEW; SPHINCTEROTOMY; SPINAL CORD; SPINAL CORD INJURY;

EID: 0031953890     PISSN: 10538135     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1053-8135(97)00055-3     Document Type: Review

References (104)

1. Blaivas JG. Mechanism of micturition. In: Scientific foundations of urology. Chisholm GD, Fair W, editors. Oxford: Heineman Medical Books, 1990:273-288.
2. Tanagho EA. Interpretation of the physiology of micturition. In: Hydrodynamics of micturition. Hinman F Jr, editor. Springfiles. Illinois: Charles C. Thomas, Publ., 1971:18-40.
3. Palmtag H. Praktische urodynamik. Gustav Fisher Verlag Stuttgart, 1977.
4. de Groat WC, Booth AM, Yoshimura N. Neurophysiology of micturition and ist modification in animal models and human disease. In: Maggi CA, editor. The autonomic nervous system. Nervous control of the urogenital system. London: Harwood Academic Publ., 1993:227-290.
5. Blaivas JG, Sinha HP, Zayed AAH, Labib KB. Detrusor-sphincter dyssynergia. J Urol 1981a;125:542-544.
6. Yalla SV, Blunt KJ, Fam BA, Constantinople NL, Gittes RF. Detrusor-urethral sphincter dyssynergia. J Urol 1977;118:1026-1029.
7. McGuire EJ, Brady S. Detrusor-sphincter dyssynergia. J Urol 1977;121:774-777.
8. Blaivas JG, Sinha HP, Zayed AAH, Labib KB. Detrusor-external sphincter dyssynergia: a detailed electromyographic study. J Urol 1981b;125:545-548.
9. Yalla SV, Rossier AB, Fam BA. Dyssynergic vesicourethral responses during bladder rehabilitation in spinal cord injury patients. J Urol 1976;115:575-579.
10. Waller L, Jonsson O, Norlen L, Sullivan L. Clean intermittent catheterization in spinal cord injury patients. Long-term followup of a hydrophilic low friction technique. J Urol 1995;153:345-348.
11. Stahl MM, Ekstrom B, Sparf B, Mattiasson A, Andersson K. Urodynamic and other effects of tolterodine: a novel antimuscarinic drug for the treatment of detrusor overactivity. Neurourol Urodyn 1995;14:647-655.
12. Mizunaga M, Miyata M, Kaneko S, Yachiku S, Chiba K. Intravesical instillation of oxybutinin hydrochloride therapy for patients with a neuropathic bladder. Paraplegia 1994;32:25-29.
13. Fowler CJ, Beck RO, Gernard S, Betts CD, Fowler CG. Intravesical capsaicin for treatment of detrusor hyperreflexia. J Neurol Neurosurg Psychiatry 1994;57:169-173.
14. Jonas U, Hohenfellner R. Late results of bladder stimulation in 11 patients. J Urol 1978;120:565-568.
15. Merril DC. Electrical vesical stimulation. Acta Urol Belg 1979;47:110-114.
16. Magasi P, Simon ZS. Electrical stimulation of the bladder and gravidity. Urol Int 1986;41:241-245.
17. Tanagho EA, Schmidt RA. Electrical stimulation in the clinical management of the neurogenic bladder. J Urol 1988;140:1331-1339.
18. Hassouna M, Li JS, Elhilali MM. Dog as an animal model for neurostimulation. Neurourol Urodyn 1994;13:159-167.
19. Grimes JH, Nashold BS, Currie DP. Chronical stimulation of the paraplegic bladder. J Urol 1973;109:242-245.
20. Grimes JH, Nashold BS. Clinical application of electronic bladder stimulation in paraplegics. Br J Urol 1974;46:653-657.
21. Nashold BS, Friedman H, Grimes J. Electrical stimulation of the conus medullaris to control bladder emptying in paraplegia: a ten-year review. Appl Neurophysiol 1982;45:40-43.
22. Carter RR, McCreery DB, Woodford BJ, Bullara LA, Agnew WF. Micturition control by microstimulation of the sacral spinal cord of the cat: acute studies. IEEE Trans Rehabil Eng 1995;3:206-214.
23. Brindley GS, Polkey CE, Rushton DN. Sacral anterior root stimulators for bladder control in paraplegia. Paraplegia 1982;20:365-381.
24. Brindley GS, Polkey CE, Rushton DN, Cardozo L. Sacral anterior root stimulators for bladder control in paraplegia: the first 50 cases. J Neurol Neurosurg Psychiatry 1986;49:1104-1114.
25. van Kerrebroeck PEV, Koldewijn E, Wijkstra H, Debruyne FMJ. Intradural sacral rhizotomies and implantation of an anterior sacral stimulator in the treatment of neurogenic bladder dysfunction after spinal cord injury: surgical technique and complications. World J Urol 1991;9:126-132.
26. Creasey GH. Electrical stimulation of the sacral roots for micturition after spinal cord injury. Urol Clin N Am 1993;20:505-515.
27. Tanagho EA, Schmidt RA, Orvis BR. Neural stimulation for control of voiding dysfunction: a preliminary report in twenty-two patients with serious neuropathic voiding disorders. J Urol 1989;142:340-345.
28. Sauerwein D, Ingunza W, Fischer J et al. Extradural implantation of sacral anterior stimulators. J Neurol Neurosurg Psychiatry 1990;53:681-684.
29. Sauerwein D. Die operative Behandlung der spastischen Blasenlahmung bei Queschnittlahmung. Urol A 1990;29:196-203.
30. Brindley GS. The first 500 patients with sacral anterior root stimulator implants: general description. Paraplegia 1994;32:795-805.
31. Schmidt RA. Advances in genitourinary neurostimulation. Neurosurgery 1986;19:1041-1044.
32. Schmidt RA, Bruschini H, Tanagho EA. Sacral root stimulation in controlled micturition (peripheral somatic neurotomy and stimulated voiding). Invest Urol 1979;17:130-134.
33. Sweeney JD, Mortimer JT, Bodner DR. Acute animal studies on electrically induced collision for collision block of motor activity. Neurourol Urodyn 1989; 8:521-536.
34. Sweeney JD, Mortimer JT, Bodner DR. Animal study of pudendal nerve cuff electrode implants for collision block of motor activity. Neurourol Urodyn 1990;9:83-93.
35. Solomonow M. External control of the neuromuscular system. IEEE Trans Biomed Eng 1984;31:752-763.
36. Ishigooka M, Hashimoto T, Sasagawa I, Izumiya K, Nakada T. Modulation of the urethral pressure by high frequency block stimulus in dogs. Eur Urol 1994;25:334-337.
37. Sweeney JD, Mortimer JT. An asymmetric two-electrode cuff generation of unidirectionally propagated action potentials. IEEE Trans Biomed Eng 1986;33:541-549.
38. Fang ZP, Mortimer JT. Selective activation of small motor axons by quasitrapezoidal current pulses. IEEE Trans Biomed Eng 1991;38:168-174.
39. Rijkhoff NJM, Koldewjin EL, van Kerrebroeck PEV, Debruyne FMJ, Wijkstra H. Selective activation of the detrusor muscle by sacral root stimulation in a canine model. Neurourol Urodyn 1993;12:381-382.
40. Rijkhoff NJM, Hoslheimer J, Koldewjin EL, Sruijk JJ, van Kerrebroeck PEV, Debruyne FMJ, Wijkstra H. Selective stimulation of sacral nerve roots for bladder control: a study by computer modeling. IEEE Trans Biomed Eng 1994a;41:413-424.
41. Rijkhoff NJM, Koldewjin EL, van Kerrebroeck PEV, Debruyne FMJ, Wijkstra H. Acute animal studies on the use of an anodal block to reduce urethral resistance in sacral root stimulation. IEEE Trans Rehabil Eng 1994b;2:92-99.
42. Rijkhoff NJM, Hendrikx LBPM, Debruyne FMJ, Wijkstra H. Electrical stimulation of ventral sacral nerve roots: selective detrusor activation in patients. Neurourol Urodyn 1995a;14:506-507.
43. Rijkhoff NJM, Holsheimer J, Debruyne FMJ, Wijkstra H. Modeling selective activation of small myelinated nerve fibers using a monopolar-point electrode. Med Biol Eng Comput 1995b;33:762-768.
44. Sassen M, Zimmermann M. Differential blocking of myelinated nerve fibers by transient depolarizing. Pflüg Arch 1973;341:179-195.
45. Grill WM, Mortimer JT. Selective activation of distant nerve fibers. Proc 15th Ann Int Conf IEEE-EMBS. San Diego, CA, 1993:1249-1250.
46. Grill WM, Mortimer JT. Stimulus waveforms for selective neural stimulation. IEEE Eng Med Biol Mag 1995;14:375-385.
47. Jünemann KP, Wipfler G, Leitzig R et al. The influence of signal shapes on selectivity and efficacy in sacral electrostimulation for emptying the canine bladder. Proc 11th Congr EAU, Berlin, Germany, 1994:289.
48. Lockhardt JL, Vorstman B, Weinstein D, Politano VA. Sphincterotomy failure in neurogenic bladder disease. J Urol 1986;135:86-89.
49. Vapnek JM, Couillard DR, Stone AR. Is sphincterotomy the best management of the spinal cord injured bladder? J Urol 1994;151:961-964.
50. Chancellor MB, Rivas DA, Linsenmeyer T et al. Multicentral trial in North America of UroLume urinary sphincter prosthesis. J Urol 1994;152:924-930.
51. Perkash I. Laser sphincterotomy and ablation of prostate using sapphire chisel contact top firing neodymium: YAG laser. J Urol 1994;152:2020-2024.
52. Juma S, Niku SD, Brodak PP, Joseph AC. Urolume urethral wallstent in the treatment of detrusor-sphincter dyssynergia. Paraplegia 1994;32:616-621.
53. Sauerwein D, Gross AJ, Kutzenberger J, Ringer RH. Wallstents in patients with detrusor-sphincter dyssynergia. J Urol 1995;154:495-497.
54. Kerner J. Vergiftung durch verdorbene Wurste. Tubinger Blatter fur Naturwissenschaften und Arzneykunde 1817;3:1-25.
55. Simpson LL. The origin, structure and pharmacologic activity of botulinum toxin. Pharmacol Rev 1981; 33:155-188.
56. DasGupta BR. The structure of botulinum neurotoxin. In: Simpson LL, editor. Botulinum neurotoxin and tetanus toxin. San Diego, CA: Academic Press, 1989:53-66.
57. Scott AB. Botulinum toxin treatment of eye muscles to correct strabismus. Trans Am Ophtalmol Soc 1981;79:734-770.
58. Kerner J. Das Fettgift oder die Fettsaure und ihre Wirkung auf den tierischen Organismus, ein Beytrag zur Untersuchung des in in verdorbenen Wursten giftig wirkenden Stoffes. Stuttgart, Tubingen Cotta, 1822.
59. National Institutes of Health Consensus Development Statement: Clinical use of botulinum toxin, Nov 12-14, 1990. Arch Neurol 1991;48:1294-1298.
60. Shiavo G, Rossetto O, Santucci A, DasGupta BR, Montecucco C. Botulinum neurotoxins are zinc proteins. J Biol Chem 1992;267:23479-23483.
61. Dolly JO, de Paiva A, Foran P, Lawrence G, Daniels-Holgate P, Ashton AC. Probing the process of transmitter release with botulinum and tetanus neurotoxins. Sem Neurosci 1994;3:3-13.
62. Foran P, Shone CC, Dolly JO. Differences in the protease activities of tetanus and botulinum B toxins revealed by cleavage of vesicle associated membrane protein and various size segments. Biochemistry 1994;33:15365-15374.
63. Dysktra DD, Sidi AA, Scott AB, Paget JM, Goldish GD. Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol 1988;139:919-922.
64. Dysktra DD, Sidi AA. Treatment of detrusor-sphincter dyssynergia with botulinum A toxin: a double-blind study. Arch Phys Med Rehabil 1990;71:24-26.
65. Schurch B, Hauri D, Largo M, Kreienbuhl B, Meyer E, Rossier AB. Effets de la toxine botulinique A sur le sphincter strie des vessies neurogenes. J Urol 1990;90:375-380.
66. Schurch B, Hauri D, Rodic B, Curt A, Meyer M, Rossier AB. Botulinum-A toxin as a treatment of detrusor-sphincter dyssynergia: a prospective study in 24 spinal cord injury patients. J Urol 1996;155:1023-1029.
67. Dyro FM. Electrophysiology of the lower urinary tract. In: Yalla SV, McGuire MJ, Elbadawi A, Blaivas J, editors. Neurourology and urodynamics. Principles and practice. New York: Macmillan Publ., ch. 1, 1989:45-58.
68. Schurch B, Yasuda K, Rossier AB. Detrusor bladder neck dyssynergia revisited. J Urol 1994;152:2066-2070.
69. Sellin LC, Thesleff S. Pre and postsynaptic actions of botulinum toxin at the rat neuromuscular junction. J Physiol 1981;317:487-495.
70. Hatheway CH. Immunology of botulinum toxin: In: Anonymus. New York: Marcell Dekker, 1993.
71. Brin MF, Blitzer A. Botulinum toxin: dangerous terminology errors. J R Soc Med 1993;86:493-494.
72. Pickett AM, Hambleton P. Dose standardisation of botulinum toxin. Lancet 1994;344:474-475.
73. Scott AB, Suzuki D. Systemic toxicity of botulinum toxin by intramuscular injection in the monkey. Mov Disord 1988;3:333-335.
74. Herrero BA, Ecklund AE, Street CS, Ford DF, King JK. Experimental botulism in monkey. A clinical pathological study. Exp Mol Pathol 1967;6:84-95.
75. Pearce LB, Borodic GE, Johnson EA, First ER, Mac Callum R. The median paralysis unit: A more pharmacologically relevant unit of biologic activity for botulinum toxin. Toxicology 1995;33:217-227.
76. Elston JS, Russel RWR. Effect of treatment with botulinum toxin on neurogenic blepharospasm. Br Med J 1985;290:1857-1859.
77. Sanders DB, Massey EW, Buckley EC. Botulinum toxin for blepharospasm. Single fiber EMG studies. Neurology 1986;36:545-547.
78. Lange DJ, Brin MF, Warner CL, Fahn S, Lovelace RE. Distant effects of local injections of botulinum toxin Muscle Nerve 1987;10:552-555.
79. Lange DJ, Brin MF, Warner CL, Fahn S, Lovelace RE. Distant effects of local injections of botulinum toxin incidence and course. Adv Neurol 1988;50:609-612.
80. Argov Z, Mastaglia FL. Disorders of neuromuscular neurotransmission caused by drugs. N Engl J Med 1979;301:409-413.
81. Jankovic J, Schwartz KS. Longitudinal experience with botulinum injections for treatment of blepharospasm and cervical dystonia. Neurology 1993;43:843-836.
82. Hatheway CH, Snyder JD, Seals JE, Edell TA, Lewis GE. Antitoxin levels in botulism patients treated with trivalent equine botulinum antitoxin to toxin types A, B, and E. J Infect Dis 1984;150:407-412.
83. Dezfulian M, Hatheway C, Yolken R, Bartlett J. Enzyme-linked immunosorbent assay for detection of Clostridium botulinum type A and type B toxins in stool samples of infants with botulism. J Clin Microbiol 1984;20:379-383.
84. Dezfulian M, Bartlett J. Detection of Clostridium botulinum type A toxin by enzyme-linked immunosorbent assay with antibodies produced in immunologically tolerant animals. J Clin Microbiol 1984;19:645-648.
85. Dezfulian M, Bitar R, Bartlett J. Kinetics study of immunological response to Clostridium botulinum toxin. J Clin Microbiol 1987;25:1336-1337.
86. Tsui JK, Wong NLM, Wong E, Calne DB. Production of circulating antibodies to botulinum-A toxin in patients receiving repeated injections for dystonia. Ann Neurol 1988;23:181 (Abstract).
87. Doellgast GJ, Triscott MX, Beard G et al. Sensitive enzyme-linked immunosorbent assay for detection of Clostridium botulinum neurotoxins A, B, and E using signal amplification via enzyme-linked coagulation assay. J Clin Microbiol 1993;31:2402-2409.
88. Doellgast GJ, Beard G, Bottoms JD et al. Enzyme-linked immunosorbent assay and enzyme-linked coagulation assay for detection of Clostridium botulinum Neurotoxin-A, Neurotoxin-B and Neurotoxin-E and solution-phase complexes with dual-label antibodies. J Clin Microbiol 1994;32:105-111.
89. Scott AB. Clostridial toxins as therapeutic agents. In: Simpson LL, editor. Botulinum neurotoxin and tetanus toxin. New York: Academic Press, 1989:399-412.
90. Greene P, Fahn S, Diamond B. Development of resistance to botulinum type A in patients with torticollis. Mov Disord 1994;9:213-217.
91. Greene P, Fahn S. Reponse to botulinum toxin F in seronegative botulinum toxin A-resistant patients. Mov Disord 1996;11:181-184.
92. Hatheway C, Dang C. Immunogenicity of the neurotoxin of clostridium botulinum. In: Jankovic J, Hallet M, editors. Therapy with botulinum toxin. New York: Marcel Dekker, 1994.
93. Siatowski RM, Tyutyunikov A, Biglan AW et al. Serum antibody production to botulinum A Toxin. Ophtalmology 1993;100:1861-1866.
94. Borodic G, Johnson E, Goodnough M, Schantz, E. Botulinum toxin therapy, immunologic resistance and problems with available materials. Neurology 1996;46:26-29.
95. Borodic GE, Pearce B, Duane D, Johnson E. Antibodies to botulinum toxin (Letter). Neurology 1995;45:204.
96. Black JD, Dolly JO. Selective location of acceptors for botulinum neurotoxin type A in the central and peripheral nervous systems. Neuroscience 1987;23:767-779.
97. Borodic GE, Cozzolino D. Blepharospasm and its treatment, with emphasis on the use of botulinum toxin. Plast Reconstr Surg 1989;83:546-554.
98. Borodic GE, Ferrante R. Effects of repeated boutulinum toxin injections on orbicularis oculi muscle. J Clin Neuroophtalmol 1992;12:12-17.
99. Harris CP, Alderson K, Nebeker J, Holds JB, Anderson RL. Histologic features of human orbicularis oculi treated with botulinum A toxin. Arch Ophtalmol 1991;109:393-395.
100. Spencer RF, McNeer KW. Botulinum toxin paralysis of adult monkey extraocular muscle. Structural alterations in orbital, singly innervated muscle fibers. Arch Opthalmol 1987;105:1703-1711.
101. Alderson K, Holds JB, Anderson RL Botulinum-induced alteration of nerve-muscle interactions in the human orbicularis oculi following treatment for blepharospasm. Neurology 1991;41:1800-1805.
102. Angaut-Petit D, Molgo J, Comella JX, Faille L, Tabti N. Terminal sprouting in mouse neuromuscular junctions poisoned with botulinum type A toxin: morphological and electrophysiological features. Neuroscience 1990;37:799-808.
103. Booth CM, Kemplay SK, Brown MC. An antibody to neural cell adhesion molecule impairs motor nerve terminal sprouting in a mouse muscle locally paralysed with botulinum toxin. Neuroscience 1990;35:85-91.
104. Tsujimoto T, Kuno M. Calcitonin gene-related peptide prevents disuse-induced sprouting of rat motor nerve terminals. J Neurosci 1988;8:3951-3957.